(Q46442554)

22 December 2017

title

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy (English)

1 reference

22 December 2017

6

W Kimryn Rathmell

1 reference

22 December 2017

author name string

Chirag Amin

1

1 reference

22 December 2017

Eric Wallen

2

1 reference

22 December 2017

Raj S Pruthi

3

1 reference

22 December 2017

Benjamin F Calvo

4

1 reference

22 December 2017

Paul A Godley

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

5 August 2008

1 reference

22 December 2017

published in

Urology

1 reference

22 December 2017

volume

72

1 reference

22 December 2017

issue

4

1 reference

22 December 2017

page(s)

864-868

1 reference

22 December 2017

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

BAY 43-9006: preclinical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.01.088

10.1016/J.UROLOGY.2008.01.088

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017